| Catalog No. | HV076016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG1-lambda2 |
|---|
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
IL21R, NILR, Interleukin-21 receptor, IL-21R, IL-21 receptor, CD360, Novel interleukin receptor, Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
Q9HBE5 & Q15116 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | Bispecificantibody, AMG256, AMG-256, AMG256, 2552814-07-8 |
|---|
| Background | Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research.Latikafusp may lead to the development of immunogenicity-mediated responses.
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
